The increase in p21 and the decrease in PCNA, along with enhanced β-galactosidase staining, indicate that FEN1 knockdown promotes a senescent phenotype in SH-SY5Y cells, potentially contributing to altered drug sensitivity and highlighting its significance in NB therapy. This evidence concerns the gene FEN1 and neuroblastoma.